Welcome to our dedicated page for FTAC Emerald Acquisition news (Ticker: EMLD), a resource for investors and traders seeking the latest updates and insights on FTAC Emerald Acquisition stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FTAC Emerald Acquisition's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FTAC Emerald Acquisition's position in the market.
FTAC Emerald Acquisition Corp. (NASDAQ: EMLDU) announced the pricing of its initial public offering, comprising 22,000,000 units priced at $10.00 each, generating gross proceeds of $220,000,000. Trading on NASDAQ is set to begin on December 16, 2021. Each unit includes one share of Class A common stock and one-half of a redeemable warrant, with the full warrant exercisable at $11.50. The offering's closing is anticipated on or about December 20, 2021. Goldman Sachs & Co. LLC acts as the sole book-running manager, with an additional 3,300,000 units available for over-allotment.